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three guiding principles at JSC
z Keep healthy astronauts healthy.
z a different approach than treating the sick
z an occupational health model
z Risk reduction -- ALARA
z we don’t study decompression sickness (DCS), we 
limit the risk.
z we don’t study acute mountain sickness (AMS), we 
limit the risk.
z we must stay non-invasive in what we do.
z Operational reality
z Use what you know, very often forced to extrapolate.
z JSC is not a medical or academic research center.
consequences of these principles 
z We do more prevention than treatment.
z We often lack specific data for specific 
questions because we respond to 
immediate needs.
z A non-invasive approach maximizes 
subject safety but limits research 
opportunity.
z We constantly assess risk as:
z the probability of the event and consequence 
of the event.
environmental physiology
z Pressure
z hypobaric and hyperbaric
z Gases
z hypoxia and hyperoxia
z hypercapnia – closed space issues
z inert gas physiology / respiration
z Temperature
z hypothermia and hyperthermia
z thermal comfort
z Protective clothing
z diving, aviation, mountaineering, space
z Acceleration
z Noise and Vibration
z Exercise / Performance
z Acclimatization / Adaptation
z engineering solutions when necessary
we don’t like rapid pressure change
environmental chambers at JSC
z Environmental Test Article
z 11-foot chamber
z 8-foot chamber
z Skylab simulation chamber
z Two hypo and two hyperbaric chambers 
z Chamber B
z “giant” thermovaccum chamber
z Neutral Buoyancy Laboratory
z Space suit / personal rescue sphere
z Thermal chamber
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reducing the risk of decompression sickness
classification of DCS
z Type I – pain-only
z “pain” as just an awareness (Grade 1)
z “pain” at a threshold (Grade 2)
z “pain” enough to impair performance, and therefore stop a test 
(Grade 3)
z Type II – serious DCS
z should stop an EVA
z could result in long-term injury, or even death
z Ultrasound monitoring for venous gas bubbles is a non-
invasive way to understand decompression stress and 
monitoring for arterial gas is a safety plan.
Doppler Ultrasound Technology
z Non-invasive measure of decompression 
stress
z Spencer 0 – IV Venous Gas Emboli Scale
z Monitor
z Pulmonary artery – all of cardiac output
z Subclavian vein
z Mid-cerebral artery – where it really matters
z Four chamber view of the heart


Tissues, especially adipose,
dump bubbles in venous system
pulmonary artery VGE video
four-chamber ultrasound video


Argo ΙΙ, 1994
exercise 
during
prebreathe
is 
now
hot
86.8%no DCS
0.8%Type II
12.5%Type I
1983 – 2007:  914 exposures, 121 cases 
of DCS with 7 classified as Type II
58.4%
VGE 0
5.2%
VGE I
6.8%
VGE II
18.9%
VGE IV
10.7%VGE III
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the probability of DCS
z simple probability models are:
P(DCS) = dose a / (dose a + b a) “Hill function”
P(DCS) = 1 - e (- dose) “survival function”
P(DCS) = 1 / (1 + e (-Bo - B1 * dose))  “logistic function”
z dose as simple one variable tissue ratio (TR)
z dose as more complex multivariable expression 
(TR, age, time, exercise, bubble volume, 
gender, etc.)

decompression sickness as dose-response
observations
model 
outcome
goodness of fit
the data we have
ambulating
non-ambulating

mild Type I DCS video
6 / 42 (14%) pain 
got worse
19 / 42 (45%) pain 
got better
17 / 42 (41%) pain 
stayed constant
Type II, or “serious” DCS
z Seven Type II cases in 914 NASA 
exposures (1983 – 2007)
z four of the seven had no O2 prebreathe
examples of serious DCS
z substernal
disturbance
z unproductive cough
z dyspnea
z disruptions of:
z motor
z sensory
z cognitive pathways in 
brain and spinal cord
z paralysis
z ataxia
z dysmetria
z vertigo
z numbness
z aphasia
z amnesia
z altered mood
more examples
z tinitus
z diplopia
z nystagmus
z hemianopsia
z confusion
z belligerence
z scatomo
z nausea
z cold sweat
z dyskinesia
z syncope
z severe headache
z vomiting
z pallor
z hallucinations
z depression

the puzzle of exercise and DCS


cutis marmorata –
several hours later!

treatment of DCS is a real challenge in spacei l ll itr t t f    r    
back to the Moon, but in a different way
we want to stay longer and do more EVA
spacecraft atmosphere trade study
z Underlying Assumptions:
z Efficient and frequent EVAs drive the exploration program.
z Low pressure suit is always preferred to high pressure suit. 
z There is an operational value to a short in-suit prebreathe. 
z Vehicle atmosphere may not prevent risk of DCS during EVA.
z Shuttle and ISS atmospheres are examples.
z Dedicated hyperbaric treatment capability may not be present.
z Atmosphere Design Considerations:
z Don’t want a significant risk of fire – NASA has bad experience 
with 100% O2.
z Limit hypoxia – you need O2 breath-by-breath.
z Prevent DCS and VGE.
z Better to prevent rather than treat DCS, or to constantly embolize
the lung.
z Optimize atmosphere to allow safe and efficient EVAs.
Environment
PB
psia mmHg
FIO2
(%)
PIO2
mmHg
PAO2
mmHg
Actual Altitude
m         feet
Equivalent Air 
Altitude
m         feet
CEV + LSAM
normal 8.0     414 32.0 117 77 4,877   16,000 1,829   6,000
best case 8.2     424 34.0 128 86 4,816   15,800 1,158   3,800
worse case 7.8     403 30.0 107 68 5,029   16,500 2,438   8,000
HABITAT
normal 7.6     393 32.0 111 71 5,182   17,000 2,286   7,500
best case 7.8     403 34.0 121 80 5,029  16,500 1,524   5,000
worse case 7.4     383 30.0 101 63 5,364  17,600 2,895   9,500
PIO2 is inspired O2 partial pressure, computed as (PB mmHg – 47) * FIO2 (as decimal fraction).
PAO2 is computed acute alveolar oxygen partial pressure from alveolar oxygen equation.
future spacecraft atmospheres
z Signs and symptoms including headache, 
nausea, dizziness, fatigue, vomiting and 
sleeplessness following a recent gain in 
altitude with at least several hours at the 
new altitude in a hypoxic environment; 
likened to a bad hangover.
Acute Mountain Sickness
incidence of AMS
z The incidence of AMS is highly variable.
z Some may show mild AMS symptoms as low as 1,981-2,438m 
(6,500 - 8,000 ft).
z One report claims that 25% of people are affected with quick 
ascent to 1,891m, with 90% of symptoms resolving in 3 – 4 days.
z Houston (1982) claims that 25-30% of people at 3,048m 
(10,000 ft) will experience some type of AMS.
z This doubles at 4,200m (14,000 ft) and nearly all people will 
show some signs of AMS by 5,486m (18,000 ft).
z Roach (1998) says about 5% of people who develop 
AMS at 3,962m (13,000 ft) will go on to develop life 
threatening pulmonary and / or cerebral edema.
“typical” response to hypobaric 
hypoxic exposure
z Ascent causes a decrease in PaO2 sensed by the 
peripheral and central chemoreceptors, leading to 
increased rate of pulmonary ventilation (VE) – but 
some show little change in VE.
z Hyperventilation in response to hypoxia increases 
PAO2 and subsequently decreases PACO2 and leads 
to a transient alkalosis. 
z There is also a hypoxia-induced diuresis as the 
kidney attempts to establish normal pH with the 
excretion of bicarbonate – but some show little 
change in urine output.
acute hypobaric hypoxia video
the spectrum of hypoxia
z A sudden ascent to high altitude could kill you 
due to acute hypoxia while a gradual ascent to 
the same altitude could result in AMS or no 
symptoms at all.
z Symptoms of AMS take longer to develop (hrs-
days).
z Severe and prolonged forms of AMS may lead to 
High Altitude Pulmonary Edema (HAPE) and 
High Altitude Cerebral Edema (HACE) and 
death.
Lake Louise AMS Scoring System
z Based on this committee’s recommendations:
z A diagnosis of AMS is based on a recent gain in altitude, at 
least several hours (>2) at the new altitude, and the presence 
of headache and at least one of the following symptoms: 
gastrointestinal upset, fatigue or weakness, dizziness or 
lightheadedness and difficulty sleeping. 
z A score of three points or greater on the AMS Self-Report 
Questionnaire alone or in combination with the clinical 
assessment score is diagnostic of AMS.
1. Headache 0 No headache
1 Mild Headache
2 Moderate Headache
3 Severe Headache, incapacitating
2. Gastrointestinal 
Symptoms 0 No gastrointestinal symptoms
1 Poor appetite or nausea
2 Moderate nausea or vomiting
3 Severe nausea & vomiting, incapacitating
3. Fatigue and/or 
Weakness 0 Not tired or weak
1 Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue / weakness, incapacitating
4. Dizziness / 
lightheadedness 0 Not Dizzy
1 Mild dizziness
2 Moderate dizziness
3 Severe dizziness, incapacitating
5. Difficulty sleeping 0 Slept as well as usual
1 Did not sleep as well as usual
2 Woke many times, poor night's sleep
3 Could not sleep at all
Self Report 
Questionnaire
Each question asked and 
the sum is calculated as 
the AMS self report score.
6. Change in Mental 
Status 0 No Change in Mental Status
1 Lethargy /  lassitude
2 Disoriented/confused
3 Stupor / semiconsciousness
4 Coma
7. Ataxia (heel to 
toe walking) 0 No Ataxia
1 Maneuvers to maintain balance
2 Steps off line
3 Falls down
4 Can't stand
8. Peripheral Edema 0 No peripheral edema
1 Peripheral edema at one location
2 Edema at two or more locations
Clinical Assessment
The interviewers ratings of 
three signs is added to the 
self-report score (Roach 
1993)
This system helped to standardize the diagnosis of AMS.
a debate is underway
z Despite over a century of research there remains 
a vigorous debate on the etiology and 
pathophysiology of AMS.
z Certainly the brain is the target organ of and 
responder to O2 deprivation.
Paul Bert  (1833-1886)
z A French Physiologist considered the 
founder of Aerospace Medicine.
z Demonstrated, that the symptoms of AMS 
could be prevented or relieved by oxygen 
breathing and so “Proved” that it was 
the decrease in partial pressure of 
oxygen  & subsequent hypoxia at high 
altitude, that caused AMS.
z This doctrine that low partial pressure of 
O2 alone is the cause for AMS has held 
true for 150 years.
Loepkky, Roach, Tucker, et al 
z But over the last thirty years, 
researchers have begun to question the 
conventional wisdom that the symptoms of 
AMS are solely due to low O2 partial 
pressure.
“the diminution of barometric pressure acts upon 
the living beings only by lowering the oxygen 
tension in the air, in the breath, and in the blood 
which supplies their tissues…. The increase in 
barometric pressure acts only by increasing 
oxygen tension in the air and blood….”  Paul 
Bert, 1878.
z Consequently, maintaining sea level equivalent partial 
pressure of O2 at any and all altitudes we “assume” no 
signs and symptoms of AMS should be seen.
Variable Pressure with Supposedly Equivalent Normoxia
A B C
21% O2 @ 760mmHg 31% O2 @ 523 mmHg 49% O2 @ 349mmHg
Sea Level 10,000 ft 20,000 ft
PAO2 = 104 mmHg PAO2 = 103 mmHg PAO2 = 104 mmHg
PAO2 = 61 mmHgPAO2 = 61 mmHgPAO2 = 61 mmHg
20,000 ft10,000 ftSea Level
32.5% O2 @ 349mmHg21% O2 @ 523 mmHg14% O2 @ 760mmHg
CBA
Variable Pressure with Supposedly Equivalent Hypoxia
Equivalent normoxic air altitudes:  A= B = C
no AMS is expected?
Equivalent hypoxic altitudes:  A = B = C
all equal time-course and incidence of AMS symptoms?
z Accumulated anecdotal evidence shows 
descent is far more effective for relief of 
AMS than enriched O2 breathing alone.
z Essentially opening the doorway for further 
investigation of an independent pressure 
factor.
Tucker, 1983
z Starts his experiments with subjects living at 1,524 m (5,000 
feet).
z Takes them to 15,000 feet on air and site pressure on 14% O2.
Normoxic, PAO2 = 
103 mmHg
Hypoxic, PAO2<103 
mmHg
Normobaric, 
PB = 760 
mmHg
Altitude 1520
PAO2 = 77
No AMS symptoms
Altitude 1520 m
PAO2 = 47.1
Mean AMS Score: 3.2
Hypobaric 
PB<760 mmHg
Altitude 4570 m 
PB = 430 mmHg
PAO2 = 45
Mean AMS Score: 6.7
Environmental Symptoms Questionnaire
Roach and Loeppky, 1996
z Confirm the effect of hypobaria on the pathophysiology of 
AMS – hypobaric hypoxia caused modest hypoventilation 
combined with mild edema relative to normobaric hypoxia.
Normoxic, PAO2 = 
103 mmHg
Hypoxic, PAO2<103 
mmHg
Normobaric, 
PB = 760 
mmHg
Altitude 1520 m
PAO2 = 76
No AMS symptoms
Altitude 1520 m
PAO2 = 47.1
Mean AMS Score: 2.0
Hypobaric 
PB<760 
mmHg
Altitude 4570 m
PAO2 = 74.5
Mean AMS score: 0.4
Altitude 4570 m 
PAO2 = 46
Mean AMS Score: 3.7
Lake Louise scoring system
the pressure effect!
z The pressure effect seems real, so to 
understand the total hypoxic stress means you 
have to understand the interaction between O2
partial pressure and ambient pressure. 
z A variety of explanations have been 
proposed for AMS and the effect of 
barometric pressure.
hypobaric hypoxia vrs normobaric hypoxia
z Decreased gas density 
relative to 1 ATA
z Decreased quantity of 
gas in solution relative to 
1 ATA
z Increased insensible 
water loss relative to 1 
ATA
z Transient N2 gradient out 
of tissues and CNS
z Potential for VGE
z Gas density at 1 ATA
z Gas in solution at 1 ATA
z Insensible water loss at 1 
ATA
z Transient N2 gradient into 
tissues and CNS
z No potential for VGE
in the past….
z NASA’s past habitats and vehicles did not 
expose the astronaut to a significant hypoxic 
condition.
z Our only experience is with the shuttle staged 
denitrogenation protocol where astronauts are at 
the physiological equivalent of 4,000 feet 
altitude.
z Likelihood of AMS almost nil.
Vision for Space Exploration 
(2004)
z Specifies the development of human 
missions to the Moon, and then Mars.
z In order to accomplish this task NASA is 
required to build new interplanetary 
spacecraft, landers, space suits, rovers 
and surface habitats.
z The atmospheres for these spacecraft, landers, surface 
habitats, and rovers will likely be hypobaric, and a little 
hypoxic.
z Future Moon and Mars missions with CEV, LSAM and 
lunar habitat will require efficient EVA egress with 
minimal prebreathe time while still avoiding DCS and 
VGE.
z The combination of hypobaria and hypoxia simulates the 
conditions encountered by mountain climbers.
SO….. 
Are we putting future astronauts at 
an increased risk for AMS ?????
Assume that we are, and develop a 
plan to mitigate the risk --- the JSC 
philosophy.
z Based on extrapolation of current research 
it seems unlikely that anyone will 
experience severe AMS. 
z The bigger issue is likely “performance”, 
we want to maximize performance.
z The bigger issue is a mitigation plan.
what happens if astronauts develop 
AMS?
performance
z We are dealing with performance issues and 
mission success, not life and death, with the 
AMS anticipated in the CEV.
z We want to maximize performance and minimize 
any medical issues that impact mission success.
z Montgomery (1989) stated that the incidence of 
AMS at 1,981m (6,500 ft) was approximately 
12% and further stated that 50% of these 
subjects took medication for relief of symptoms.
prevention and treatment of AMS
z Preadaptation
z Preselection
z The best predictor of AMS is history of prior 
episodes.
z Mild AMS is treated by: 
z Halting or slowing ascent 
z Acclimatization
z Acetazolamide (125-250 mg BID)
z O2 therapy via mask or canula
other considerations
z Potential negative synergy between mild 
hypoxia and adaptation to μG.
z Does μG change the incidence of AMS? 
z redistribution of lung fluid
z increased interstitial edema
z altered incidence of HAPE?
optimum HCT for O2 transport
anticipated work in environmental physiology
z NASA / JSC has worked with:
z USAF
z Brooks AFB 
z Write-Patterson AFB in the distant future
z Canadian Space Agency
z DR&D – Toronto
z Japanese Space Agency
z Universities / Medical Centers
z Duke University
z University of Texas
z University of Pennsylvania
z Mayo – looking to the future
potential work to do in DCS
z Quantify PFO as a risk factor toward serious DCS.
z Understand the role of micronuclei in the genesis of 
bubbles.
z Consequence of air break in prebreathe – in progress.
z Exercise and accelerated N2 washout.
z Exercise and change in micronuclei distribution.
z Validation of the current denitrogenation procedure for lunar 
EVAs.
z Data Mining -- Biophysical / statistical modeling of DCS.
z Effective DCS treatment at remote sites.
z Gender and risk of DCS and VGE.
z Application of ultrasound technology to monitor and 
understand decompression stress.
z Use of argon as an inert gas available on Mars.
potential work to do in AMS
z Quantify the risk and impact of AMS for modest 
hypoxic exposures.
z Specific experiments about AMS based on the 
atmospheres and conditions for the proposed 
CEV, LSAM, and surface habitats.
z Determine who may be at risk for developing 
AMS.
z Understanding the physics and physiology of the 
ambient pressure effect on AMS.
z Validate risk mitigation plans for AMS.

thank you from the 
folks at JSC
johnny.conkin-1@nasa.gov
